Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (70)

I-003Oliver Ackaert

Exposure–Response Analyses of Erdafitinib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Wednesday 10:30-12:00

I-006Ludovica Aiello

Quantitative evaluation of RC-106 antitumor activity in GBM spheroids through tumor growth inhibition modeling based on cell counts data

Wednesday 10:30-12:00

I-007Arwa Alghaith

Application of a population pharmacokinetic model of olaparib in patients with recurrent glioblastoma and non-small cell lung cancer

Wednesday 10:30-12:00

I-008Engi Algharably

Population Pharmacokinetics of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Wednesday 10:30-12:00

I-014Ahmed Ibrahim Abdelaziz Atta

Quantitative Modeling of Radiation-Induced Immune Response in Normal Lung Tissue

Wednesday 10:30-12:00

I-017Sally Babiker

Characterising the effect of sex differences in the exposure and safety profile of anticancer chemotherapies

Wednesday 10:30-12:00

I-025Pauline Bambury

Exploration of optimal monoclonal antibody properties using a target-mediated drug disposition framework and the InSilicoTrials’ platform for study design simulations

Wednesday 10:30-12:00

I-028Paul Baverel

A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3

Wednesday 10:30-12:00

I-029Tassadit Belabbas

A semi-mechanistic pharmacokinetic-pharmacodynamic model to characterize thrombocytopenia in patients with biliary tract cancer, and advanced or metastatic solid tumors for a selective antagonist of MDM2-p53 interaction

Wednesday 10:30-12:00

I-033Daniel Bending

Integrating Clinical Utility Index in Early Phase Oncology Trials: A Case Study with Antibody-Drug Conjugates

Wednesday 10:30-12:00

I-042Sieto Bosgra

Antibody pairs inducing selective clustering on cells co-expressing two antigens – a HexElect QSP model

Wednesday 10:30-12:00

I-046Myriam Briki

Population Pharmacokinetics of Intravenous Methotrexate: A Model-Based Meta-Analysis Integrating Individual Patient Data from Three Independent Studies

Wednesday 10:30-12:00

I-048Chloé Burlot

Assessment of S65487 PK differences from therapeutic doses to microdose: exploring linear and nonlinear processes

Wednesday 10:30-12:00

I-050Elio Campanile

An enhanced PBPK model for predicting mRNA-encoded therapeutic trafficking in mice

Wednesday 10:30-12:00

I-063Sheng Yuan Chin

Use of physiologically-based pharmacokinetic modelling to assess the drug-disease interaction of caffeine in cancer subjects and the influence of cytokine-mediated CYP1A2 suppression

Wednesday 10:30-12:00

I-074Sinziana Cristea

A semi-mechanistic approach to model simultaneously the ADC, total mAb and cytotoxic payload of sacituzumab tirumotecan

Wednesday 10:30-12:00

I-081Anna Dari

Semi-mechanistic model of antitumor response after oncolytic virus administration

Wednesday 10:30-12:00

I-082Hippolyte Darre

A Physiologically Based Pharmacokinetic Model for Pemetrexed in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III

Wednesday 10:30-12:00

I-089Birses Debir

Application of Quantitative Systems Pharmacology (QSP) Approach to Guide Development of a Bispecific CD40-EpCAM Antibody, KK2269.

Wednesday 10:30-12:00

I-094LEKSHMI DHARMARAJAN

Model-informed scheduling of drug combinations for optimal treatment of cancer: a case study of JDQ443 and TNO155 dose regimen optimization

Wednesday 10:30-12:00

I-096Giovanni Di Veroli

A new model of Tumor Growth Inhibition for pseudo-progression in Immuno-Oncology

Wednesday 10:30-12:00

I-105Salome Dumasdelage

Translational modeling of Tumor Growth Inhibition of an antibody-drug conjugate in Oncology

Wednesday 10:30-12:00

I-108Raunak Dutta

Translational Modeling of ADC Efficacy and Hematological Toxicity: A QSP Approach for FIH Dose Recommendation with T-DM1 as an Exemplar

Wednesday 10:30-12:00

I-115Loic Etheve

A Physiologically Based Pharmacokinetic Model for Osimertinib in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III

Wednesday 10:30-12:00

II-003Xiaoqing Fan

Time-to-event analysis of iron homeostasis to inform survival in cancer patients

Wednesday 15:30-17:00

II-019Anaïs Glatard

Expediting MIDD evidence generation to support quizartinib approval in newly diagnosed AML patients.

Wednesday 15:30-17:00

II-022Janice Goh

An in vitro to in vivo translational framework for the prediction of drug efficacy in preclinical cell line derived xenografts

Wednesday 15:30-17:00

II-032Gustavo Guerrero

Model-Based Analysis of RO7589831 Mechanisms of Action in a MSI Cell Line

Wednesday 15:30-17:00

II-038Lisa Hanquet

Model informed drug development and CAR-T cells : A review of their use and credibility assessment in the context of EMA centralized procedures

Wednesday 15:30-17:00

II-049Heinrich Huber

Can the PK drivers of anti-tumour response be xenograft specific

Wednesday 15:30-17:00

II-050Katrina Hui

Population pharmacokinetic (PPK) modeling analyses of tovorafenib in patients with RAF-altered, relapsed/refractory (r/r) pediatric low-grade glioma (pLGG), advanced solid tumors, and healthy adults

Wednesday 15:30-17:00

II-051Olga Ivanova

Analysis of Itacitinib effect on the biomarkers of inflammatory response in subjects with hematological malignancies treated with CAR-T therapy

Wednesday 15:30-17:00

II-055Candice Jamois

An Integrative Pharmacometric Approach Supports the Dose Selection Proposal of Englumafusp Alfa, a New Molecular Entity with No Single Agent Activity Developed in Combination

Wednesday 15:30-17:00

II-058Tamara Jordens

PET-Guided Physiologically-Based Pharmacokinetic Modeling of tyrosine kinase inhibitors in NSCLC patients with brain metastases

Wednesday 15:30-17:00

II-061Patrick Joyce

Investigating the Impact of the Binding Site Barrier on Antibodies: A Comparative Study of ODE and PDE Models

Wednesday 15:30-17:00

II-078Hyeonji Kim

Population Pharmacokinetic Modeling and Covariate Analysis of Lenalidomide in Renally Impaired Patients with Multiple Myeloma

Wednesday 15:30-17:00

II-082Kenneth Koh

Physiologically-based pharmacokinetic (PBPK) modelling for predicting drug-disease interactions: Suppression of CYP3A4 by interleukin-6 in cancer populations

Wednesday 15:30-17:00

II-087Vasiliki Kostiou

Mechanistic modelling of CAR T-cell therapy for multiple myeloma to assess multi-antigen targeting and identify factors associated with response.

Wednesday 15:30-17:00

II-095Marie Lambert

Translational PK/PD modeling to support First-In-Human clinical trial of a MAT2A inhibitor

Wednesday 15:30-17:00

II-104Apolline Lefevre

Trimeric Complexes: The key to optimizing T-cell Bispecifics (TCB) efficacy and safety

Wednesday 15:30-17:00

II-110Adéle L'Hostis

A Physiologically Based Pharmacokinetic Model for Cisplatin in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III

Wednesday 15:30-17:00

II-113Hyeongseok Lim

Population Pharmacokinetic and Pharmacodynamic modeling Analysis of rhIL-7-hyFc, a hybrid Fc-Fused Long-Acting Interleukin-7, to support Optimal Dose Regimens in Patients with Solid Cancer

Wednesday 15:30-17:00

III-014Madalena M. A. Peyroteo

Assessing tobemstomig binding dynamics through integrated experimental and computational modeling approaches to inform therapeutic dosing

Thursday 9:50-11:45

III-021Mathilde Marchand

Operating Characteristics of M-protein Dynamic Metrics to Support Early Decisions in Multiple Myeloma

Thursday 9:50-11:45

III-022John Maringwa

Projecting median survival times for studies with immature survival data to support accelerated approval considerations of treatments in multiple myeloma

Thursday 9:50-11:45

III-030Assil Merlaud

Characterizing the organ-specific association between tumor dynamics and overall survival across cancer types and studies: a Bayesian meta-regression

Thursday 9:50-11:45

III-047Arnaud Nativel

Prospective validation of an EGFR-Mutated NSCLC mechanistic computational disease model: predicting the combination treatment efficacy of phase III clinical trial

Thursday 9:50-11:45

III-059Eric Novik

A Semi-Mechanistic Longitudinal Gaussian Process Regression Model for Estimating Tumor Response to Treatment

Thursday 9:50-11:45

III-067Seshasai Pallikonda Chakravarthy

QSP Platform Model for Predicting Clinical Efficacy & CRS in CD3xHLA-G T-Cell Engagers (TCEs) for Solid Tumors

Thursday 9:50-11:45

III-074Suemin Park

Cell-level Pharmacodynamics-Mediated Drug Disposition Model for GI-102 (CD80/IL2v3) in Patients with Advanced or Metastatic Solid Tumors

Thursday 9:50-11:45

III-076Zinnia P Parra-Guillen

A population modelling framework to support early clinical development of BI-1910, an agonist monoclonal antibody to tumor necrosis factor 2

Thursday 9:50-11:45

III-078Mark Penney

Predicting the pharmacokinetics of T-Cell Engagers as a function of Target-Mediated Drug Disposition

Thursday 9:50-11:45

III-080Mariana Pereira

PBPK Modeling of Repurposed HIV Drugs in Prostate Cancer and the Influence of Patient Physiology

Thursday 9:50-11:45

III-096Ana Quiroga-Campano

Preclinical PK/PD/Efficacy modelling to guide early clinical dose selection for AZD9750, a novel oral Androgen Receptor Proteolysis-targeting chimera (AR-PROTAC)

Thursday 9:50-11:45

III-104Emily Roashan

Population Pharmacokinetic (PK) and mechanistic Pharmacodynamic (PD) model analysis of PHI data for FS222, a CD137/PD-L1 tetravalent, bispecific antibody which elicits robust pharmacodynamic activity in advanced solid tumor patients in a FIH study

Thursday 9:50-11:45

III-105Anne Rodallec

Model-driven scheduling of a novel anti-cancer prodrug administered subcutaneously

Thursday 9:50-11:45

III-115Razan Sakran

Personalizing Busulfan Exposure in Hematopoietic Cell Transplantation

Thursday 9:50-11:45

IV-008Celine Sarr

Application of Model-Informed Drug Development for Dose Optimization of Brigimadlin in Patients with Dedifferentiated Liposarcoma

Thursday 15:00-16:45

IV-009Tomohiro Sasaki

QSP modeling of OPB-171775, a PDE3A-SLFN12 molecular glue to predict clinical respose in patients with gastrointestinal stromal tumor (GIST).

Thursday 15:00-16:45

IV-010Adriana Savoca

A mechanistic framework for interpretation and prediction of the PKPD/anti-tumour activity relationship of irreversible Tyrosine Kinase Inhibitors (TKIs) targeting EGFR Exon20Ins mutation

Thursday 15:00-16:45

IV-024Meemansa Sood

Population time-activity modeling and simulation supporting the reduced dosimetry collection for radioligand therapy (RLT) clinical trials

Thursday 15:00-16:45

IV-028Juliane Staudinger

Covariate Analysis of Metabolizing Enzymes and Efflux Transporters and Model based Therapeutic Drug Monitoring in Females Receiving Olaparib

Thursday 15:00-16:45

IV-040Ileana Theofili

Predicting VEGF Levels in Cancer Patients Using Machine and Deep Learning

Thursday 15:00-16:45

IV-046Elena Maria Tosca

Translating Preclinical Insights into Clinical Outcomes: A Predictive Framework for Overall response rate and time to progression in Solid Tumors

Thursday 15:00-16:45

IV-060Debra van Asten

Quantifying the exposure-toxicity relationship of [177Lu]Lu-PSMA-I&T using a population PK-PD model

Thursday 15:00-16:45

IV-079Dimitrios Voulgarelis

Translational PK/PD-Efficacy modelling for camizestrant (SERD)

Thursday 15:00-16:45

IV-084Yan Wang

Alternative Model-Based Dosing Strategies for Subcutaneous Nivolumab to Improve Cost-Effectiveness in NSCLC Patients

Thursday 15:00-16:45

IV-090Mélanie Wilbaux

Population Pharmacokinetic Analysis Supporting Fixed and Extended-Interval Dosing of Balstilimab Alone and Combined with Botensilimab in Advanced Solid Tumors

Thursday 15:00-16:45

IV-094Jen-Hao Wu

Population modeling to exploit Phase I dose-finding trials data in pediatric oncology exemplified by brigatinib (ITCC-098) and bosutinib (ITCC-054)

Thursday 15:00-16:45

IV-100Tianwu Yang

Development of A Population Pharmacokinetic Model of Busulfan in Pediatric Patients

Thursday 15:00-16:45